Expand all sections

Dupilumab

Dupixent

Extended indication Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma.
Therapeutic value Possible added value for a subgroup
Total cost 600,000.00
Registration phase Clinical trials

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information